NICE IDs

16/12/2025

ID6211: Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma

16/12/2025

ID6291: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable

15/12/2025

ID4004: Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer

15/12/2025

ID6256: Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer

13/11/2025

ID6347: Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

22/10/2025

ID6202: Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma

16/10/2025

ID6452: Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

08/10/2025

ID6408: For treating moderate to severe chronic hand eczema

07/10/2025

ID6434: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor

07/10/2025

ID6255: Cabotegravir for preventing HIV-1 in adults and young people

07/10/2025

ID6434: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor

04/09/2025

ID5073: Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

03/09/2025

TA1096: Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis

28/08/2025

ID6394: Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over

26/08/2025

TA1052:Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal)

18/08/2025

ID6212:Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments

14/08/2025

ID6145: Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12)

08/08/2025

ID6332: Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable

07/08/2025

ID547: Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over

01/08/2025

ID6266: Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis